Anbio Biotechnology (NNNN) Financials

Anbio Biotechnology (NNNN) reported diluted earnings per share of $0.15 for fiscal year 2025. This represents a 162.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Anbio Biotechnology (NNNN) had a gross margin of 87.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Anbio Biotechnology (NNNN) had an operating margin of 66.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Anbio Biotechnology (NNNN) had a net profit margin of 74.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Anbio Biotechnology (NNNN) has a return on equity of 21.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Anbio Biotechnology (NNNN) recorded an outflow of $6.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Anbio Biotechnology (NNNN) had $30.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Anbio Biotechnology (NNNN) invested $201K in research and development during fiscal year 2025.

Anbio Biotechnology (NNNN) had a current ratio of 344.31 as of fiscal year 2025, which is generally considered healthy.

Anbio Biotechnology (NNNN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Anbio Biotechnology (NNNN) had a return on assets of 21.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Anbio Biotechnology (NNNN) trades at 24.5x earnings, its market capitalization divided by net income of $6.4M net income, FY2025. The market capitalization is $156.7M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Anbio Biotechnology (NNNN) trades at 18.1x sales, its market capitalization divided by revenue of $8.6M revenue, FY2025. The market capitalization is $156.7M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Anbio Biotechnology (NNNN) held $11.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.7M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Anbio Biotechnology (NNNN) has an Altman Z-Score of 1073.55, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Anbio Biotechnology (NNNN) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

For every $1 of reported earnings, Anbio Biotechnology (NNNN) used $1.05 of operating cash (-$6.7M OCF vs $6.4M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Anbio Biotechnology (NNNN) scores 71 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.